World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
55
Citations
9077
World Ranking
3826
National Ranking
163

Geoffrey A. Pietersz publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Geoffrey A. Pietersz sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 202 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Geoffrey A. Pietersz D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Geoffrey A. Pietersz sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 55 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Geoffrey A. Pietersz is affiliated with the Baker IDI Heart and Diabetes Institute in Australia. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on several subfields including Molecular Biology, Immunology, Surgery, Hematology, and Biomedical Engineering.

The scientist's work is concentrated on a range of topics related to inflammation, cardiovascular health, and nanotechnology. Key areas of study include:

  • Adipokines, Inflammation, and Metabolic Diseases
  • Atherosclerosis and Cardiovascular Diseases
  • Nanoplatforms for cancer theranostics
  • Lipoproteins and Cardiovascular Health
  • Extracellular vesicles in disease
  • Nanoparticle-Based Drug Delivery
  • Inflammasome and immune disorders

Geoffrey A. Pietersz has contributed to a number of scientific publications, with recent papers covering topics in nanobiotechnology, inflammatory diseases, and novel therapeutic approaches. Notable recent papers include:

  • In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications, 2022, Journal of Nanobiotechnology
  • C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond, 2020, Sub-cellular biochemistry/Subcellular biochemistry
  • Near-infrared light-responsive liposomes for protein delivery: Towards bleeding-free photothermally-assisted thrombolysis, 2021, Journal of Controlled Release
  • Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases, 2022, Pharmacology & Therapeutics
  • Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis, 2022, Journal of Nanobiotechnology

The scientist frequently collaborates with several researchers, with multiple co-authored publications. Frequent co-authors include:

  • Karlheinz Peter
  • Johannes Zeller
  • Xiaowei Wang
  • James D. McFadyen
  • Steffen U. Eisenhardt

Geoffrey A. Pietersz regularly publishes in venues such as:

  • Journal of Nanobiotechnology
  • Sub-cellular biochemistry/Subcellular biochemistry
  • Journal of Controlled Release
  • Pharmacology & Therapeutics
  • EMBO Molecular Medicine

Best Publications

  • Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors

    Theodora Fifis;Anita Gamvrellis;Blessing Crimeen-Irwin;Geoffrey A Pietersz

  • Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

    P. Mark Hogarth;P. Mark Hogarth;P. Mark Hogarth;Geoffrey A. Pietersz;Geoffrey A. Pietersz;Geoffrey A. Pietersz

  • Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

    V. Karanikas;L.-A. Hwang;J. Pearson;C.-S. Ong

  • OXIDATIVE/REDUCTIVE CONJUGATION OF MANNAN TO ANTIGEN SELECTS FOR T1 OR T2 IMMUNE RESPONSES

    Vasso Apostolopoulos;Geoffrey A. Pietersz;Bruce E. Loveland;Mauro S. Sandrin

  • Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

    Vasso Apostolopoulos;Geoffrey A Pietersz;Anastasios Tsibanis;Annivas Tsikkinis

  • Mannan-MUC1 - Pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma

    Bruce E Loveland;Anne Zhao;Shane C White;Hui K Gan

  • Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo

    Kuo-Ching Sheng;Martha Kalkanidis;Dodie S. Pouniotis;Sandra Esparon

  • Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

    Vasso Apostolopoulos;Geoffrey A. Pietersz;Ian F.C. McKenzie

  • Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy.

    Gabriela Minigo;Anja Scholzen;Choon K Tang;Jennifer C Hanley

  • Antibody conjugates for the treatment of cancer

    Geoffrey A. Pietersz;Ian F. C. McKenzie

  • Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells

    Kuo-Ching Sheng;Dodie Pouniotis;Mark Dexter Wright;Choon K Tang

  • Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway

    Vasso Apostolopoulos;Geoffrey A. Pietersz;Siamon Gordon;Luisa Martinez-Pomares

  • Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

    Vasso Apostolopoulos;Nadine Barnes;Geoffrey A Pietersz;Ian F.C McKenzie

  • Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity.

    Martha Kalkanidis;Geoffrey A Pietersz;Sue Dong Xiang;Patricia L Mottram

  • Cell-penetrating peptides: Application in vaccine delivery

    Nicole A. Brooks;Nicole A. Brooks;Dodie S. Pouniotis;Choon-Kit Tang;Vasso Apostolopoulos

  • Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.

    Stamatis Vassilaros;Anastasios Tsibanis;Annivas Tsikkinis;Geoffrey A Pietersz;Geoffrey A Pietersz;Geoffrey A Pietersz

  • Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.

    Vaios Karanikas;Grenville Thynne;Paul Mitchell;Chin-Swee Ong

  • Structure and Design of Polycationic Carriers For Gene Delivery

    Geoffrey A. Pietersz;Choon-Kit Tang;Vasso Apostolopoulos

  • Studies of Methotrexate-Monoclonal Antibody Conjugates for Immunotherapy

    Jerry Kanellos;Geoffrey A. Pietersz;Ian F. C. McKenzie

  • The murine Fc receptor for immunoglobulin: purification, partial amino acid sequence, and isolation of cDNA clones.

    M L Hibbs;I D Walker;L Kirszbaum;G A Pietersz

Frequent Co-Authors

Ian F. C. McKenzie
Ian F. C. McKenzie University of Melbourne
Vasso Apostolopoulos
Vasso Apostolopoulos RMIT University
Mark J. Smyth
Mark J. Smyth QIMR Berghofer Medical Research Institute
P. Mark Hogarth
P. Mark Hogarth Burnet Institute
Karlheinz Peter
Karlheinz Peter Baker IDI Heart and Diabetes Institute
Jonathan B. Baell
Jonathan B. Baell Monash University
Magdalena Plebanski
Magdalena Plebanski RMIT University
Mark D. Wright
Mark D. Wright Monash University
Eric C. Reynolds
Eric C. Reynolds University of Melbourne
Sarah M. Russell
Sarah M. Russell Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding your qualifications through related healthcare degrees can open many doors. Transitioning into specialized nursing roles such as Acute Care Nurse Practitioner programs provides advanced clinical expertise critical for acute patient management. These programs often build on existing nursing skills and offer a pathway to higher responsibility and impact.

Accelerated nurse practitioner programs are an excellent option for individuals seeking a faster track into advanced nursing roles. They combine rigorous coursework with practical experience, enabling students to enter the workforce sooner while maintaining high standards of care. For aspiring nurses without a prior degree, online RN programs for non nurses in Florida offer accessible routes to enter the nursing profession flexibly.

Understanding salary prospects is also key when choosing a career path. Reviewing data such as the average DNP salary by state helps prospective students align their educational investments with their financial goals. Combining these insights with targeted education can lead to rewarding careers in healthcare, research, and patient care, especially within the growing field of Immunology.

Explore more about dnp salary, acute care nurse practitioner programs, accelerated nurse practitioner program, and online rn programs for non nurses in florida to find the best fit for your career objectives.

Best Scientists Citing Geoffrey A. Pietersz

Trending Scientists

Recently Published Articles